Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: February 7, 2023

Details for Patent: 8,841,310

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,841,310
Title:Combinations of a pyrimidine containing NNRTI with RT inhibitors
Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Inventor(s): Stoffels; Paul (Hoogstraten, BE)
Assignee: Janssen R & D Ireland (Eastgate Village, Eastgate Little Island, Co. Cork, IE)
Application Number:12/574,881
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,841,310
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use; Device;

Drugs Protected by US Patent 8,841,310

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc COMPLERA emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate TABLET;ORAL 202123-001 Aug 10, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF HIV INFECTION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,841,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03103275Sep 3, 2003
03103319Sep 8, 2003
03103335Sep 10, 2003
03103668Oct 2, 2003

International Family Members for US Patent 8,841,310

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1610 See Plans and Pricing
African Regional IP Organization (ARIPO) 2109 See Plans and Pricing
African Regional IP Organization (ARIPO) 2296 See Plans and Pricing
African Regional IP Organization (ARIPO) 2487 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.